1-3 of 3
Ying Zou, MD
Close
Sort by
Journal Articles

Concurrent Treatment with Pim Kinase Inhibitor Downregulates Alternative Non-Homologous End-Joining Repair and Decreases Genomic Instability in FLT3-ITD Cells Treated with Topoisomerase 2 Inhibitor Chemotherapy Drugs

Kshama A. Doshi, PhD, Shivani Kapoor, MS, Ying Zou, MD PhD, Xiang Li, PhD, Mario Scarpa, MS, Nidal Muvarak, PhD, Pratik Nagaria, PhD, Olga Goloubeva, PhD MSc, Adriana E. Tron, PhD, Charles J. Bieberich, PhD, Feyruz V. Rassool, BSc, PhD, Maria R. Baer, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1243.
https://doi.org/10.1182/blood.V130.Suppl_1.1243.1243
Published: 2017
Journal Articles

Plasma Cell Leukemia (PCL): Clinical Characteristics, Outcomes, and the Impact of Circulating Plasma Cells (CPC) Percentage — A Single Center Experience

Noa G. Holtzman, MD, Olga Goloubeva, PhD MSc, Zeba Singh, MBBS, Sameer Sawhney, MD, Ying Zou, MD PhD, Jean Yared, MD, Nancy M. Hardy, MD, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Ashraf Z. Badros, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3035.
https://doi.org/10.1182/blood.V130.Suppl_1.3035.3035
Published: 2017
Journal Articles

Efficacy of Conventional Cytogenetics and FISH for EGR1 To Detect Deletion 5q in Hematological Disorders and To Assess Response to Treatment with Lenalidomide.

Ying Zou, MD, Stephanie Fink, Kimberly Stockero, Sarah Paternoster, Stephanie Smoley, Han Tun, M.D., Craig Reeder, M.D., Ayalew Tefferi, M.D., Gordon Dewald, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2351.
https://doi.org/10.1182/blood.V108.11.2351.2351
Published: 2006